Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Story continues NOT FOR DISTRIBUTION TO U.S. The Private Placement is expected to close on or about January 26, 2022, subject to satisfaction of customary closing conditions. No securities were offered or sold to Canadian residents in connection with the Private Placement.
The net proceeds of the Private Placement will be used by the Company for general working capital purposes. is acting as the exclusive placement agent for the Private Placement. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD$0.50 per Common Share for a period of five years following the issuance date. Pursuant to the Private Placement, the Company will issue 12,500,000 Common Shares (or Common Share equivalents) and Warrants to purchase up to an aggregate of 12,500,000 Common Shares at a purchase price of CAD$0.40 per Common Share and associated Warrant. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has entered into a securities purchase agreement with a single institutional investor for a private placement of its common shares (" Common Shares") (or Common Share equivalents) and warrants to purchase Common Shares (" Warrants") for gross proceeds of approximately CAD$5 million (the " Private Placement"). TORONTO, ON / ACCESSWIRE / Janu/ Novamind Inc.
0 kommentar(er)
